Unknown

Dataset Information

Adjuvant metronomic tegafur-uracil is associated with poorer outcomes and unfavorable histopathologic progression in oral squamous cell carcinomas.


ABSTRACT:

Background/purpose

Tegafur-uracil (UFUR) is widely prescribed as metronomic adjuvant chemotherapy for oral squamous cell carcinoma (OSCC) in East Asia, though its long-term benefit remains unclear. This study aimed to evaluate the oncologic and pathological impact of adjuvant UFUR in a large real-world OSCC cohort spanning three decades.

Materials and methods

This retrospective, single-institution cohort included 2048 patients with histopathologically confirmed OSCC treated at a tertiary medical center in Taiwan (1990-2020). All underwent curative-intent surgery with or without postoperative radiotherapy or concurrent chemoradiotherapy (CCRT). Among them, 878 patients received adjuvant metronomic UFUR for ≥12 months. Survival outcomes were analyzed using Kaplan-Meier and Cox

SUBMITTER: Hung KF 

PROVIDER: S-EPMC12826014 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature